Medical Devices & Consumables
Global Coronary Drug-Eluting Stent Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 608178
- Pages: 153
- Figures: 166
- Views: 1
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Coronary Drug-Eluting Stent market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Medtronic
Boston Scientific
Abbott
B.Braun
Biosensors International
MicroPort
Lepu Medical
Terumo
Blue Sail Medical
SINOMED
Liaoning Yinyi Biological
Segment by Type
Polymer Stent
Polymer-Free Stent
Others
Segment by Application
Hospital
Clinic
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Coronary Drug-Eluting Stent study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Coronary Drug-Eluting Stent market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Medtronic
Boston Scientific
Abbott
B.Braun
Biosensors International
MicroPort
Lepu Medical
Terumo
Blue Sail Medical
SINOMED
Liaoning Yinyi Biological
Segment by Type
Polymer Stent
Polymer-Free Stent
Others
Segment by Application
Hospital
Clinic
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Coronary Drug-Eluting Stent study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Coronary Drug-Eluting Stent: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Coronary Drug-Eluting Stent Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Polymer Stent
1.2.3 Polymer-Free Stent
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Coronary Drug-Eluting Stent Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Coronary Drug-Eluting Stent Revenue Estimates and Forecasts 2020-2031
2.2 Global Coronary Drug-Eluting Stent Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Coronary Drug-Eluting Stent Sales Estimates and Forecasts 2020-2031
2.4 Global Coronary Drug-Eluting Stent Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Coronary Drug-Eluting Stent Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Coronary Drug-Eluting Stent Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Polymer Stent Market Size by Manufacturers
3.5.2 Polymer-Free Stent Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Coronary Drug-Eluting Stent Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Coronary Drug-Eluting Stent Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Coronary Drug-Eluting Stent Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Coronary Drug-Eluting Stent Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Coronary Drug-Eluting Stent Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
6.4 North America Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Coronary Drug-Eluting Stent Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
7.4 Europe Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Coronary Drug-Eluting Stent Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Coronary Drug-Eluting Stent Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
9.4 Central and South America Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Coronary Drug-Eluting Stent Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Coronary Drug-Eluting Stent Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Medtronic
11.1.1 Medtronic Corporation Information
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.1.4 Medtronic Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Medtronic Coronary Drug-Eluting Stent Sales by Product in 2024
11.1.6 Medtronic Coronary Drug-Eluting Stent Sales by Application in 2024
11.1.7 Medtronic Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.1.8 Medtronic Coronary Drug-Eluting Stent SWOT Analysis
11.1.9 Medtronic Recent Developments
11.2 Boston Scientific
11.2.1 Boston Scientific Corporation Information
11.2.2 Boston Scientific Business Overview
11.2.3 Boston Scientific Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.2.4 Boston Scientific Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Boston Scientific Coronary Drug-Eluting Stent Sales by Product in 2024
11.2.6 Boston Scientific Coronary Drug-Eluting Stent Sales by Application in 2024
11.2.7 Boston Scientific Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.2.8 Boston Scientific Coronary Drug-Eluting Stent SWOT Analysis
11.2.9 Boston Scientific Recent Developments
11.3 Abbott
11.3.1 Abbott Corporation Information
11.3.2 Abbott Business Overview
11.3.3 Abbott Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.3.4 Abbott Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Abbott Coronary Drug-Eluting Stent Sales by Product in 2024
11.3.6 Abbott Coronary Drug-Eluting Stent Sales by Application in 2024
11.3.7 Abbott Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.3.8 Abbott Coronary Drug-Eluting Stent SWOT Analysis
11.3.9 Abbott Recent Developments
11.4 B.Braun
11.4.1 B.Braun Corporation Information
11.4.2 B.Braun Business Overview
11.4.3 B.Braun Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.4.4 B.Braun Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 B.Braun Coronary Drug-Eluting Stent Sales by Product in 2024
11.4.6 B.Braun Coronary Drug-Eluting Stent Sales by Application in 2024
11.4.7 B.Braun Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.4.8 B.Braun Coronary Drug-Eluting Stent SWOT Analysis
11.4.9 B.Braun Recent Developments
11.5 Biosensors International
11.5.1 Biosensors International Corporation Information
11.5.2 Biosensors International Business Overview
11.5.3 Biosensors International Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.5.4 Biosensors International Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Biosensors International Coronary Drug-Eluting Stent Sales by Product in 2024
11.5.6 Biosensors International Coronary Drug-Eluting Stent Sales by Application in 2024
11.5.7 Biosensors International Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.5.8 Biosensors International Coronary Drug-Eluting Stent SWOT Analysis
11.5.9 Biosensors International Recent Developments
11.6 MicroPort
11.6.1 MicroPort Corporation Information
11.6.2 MicroPort Business Overview
11.6.3 MicroPort Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.6.4 MicroPort Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 MicroPort Recent Developments
11.7 Lepu Medical
11.7.1 Lepu Medical Corporation Information
11.7.2 Lepu Medical Business Overview
11.7.3 Lepu Medical Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.7.4 Lepu Medical Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Lepu Medical Recent Developments
11.8 Terumo
11.8.1 Terumo Corporation Information
11.8.2 Terumo Business Overview
11.8.3 Terumo Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.8.4 Terumo Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Terumo Recent Developments
11.9 Blue Sail Medical
11.9.1 Blue Sail Medical Corporation Information
11.9.2 Blue Sail Medical Business Overview
11.9.3 Blue Sail Medical Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.9.4 Blue Sail Medical Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Blue Sail Medical Recent Developments
11.10 SINOMED
11.10.1 SINOMED Corporation Information
11.10.2 SINOMED Business Overview
11.10.3 SINOMED Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.10.4 SINOMED Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 SINOMED Recent Developments
11.11 Liaoning Yinyi Biological
11.11.1 Liaoning Yinyi Biological Corporation Information
11.11.2 Liaoning Yinyi Biological Business Overview
11.11.3 Liaoning Yinyi Biological Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.11.4 Liaoning Yinyi Biological Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Liaoning Yinyi Biological Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Coronary Drug-Eluting Stent Industry Chain
12.2 Coronary Drug-Eluting Stent Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Coronary Drug-Eluting Stent Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Coronary Drug-Eluting Stent Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Coronary Drug-Eluting Stent Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Coronary Drug-Eluting Stent Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Coronary Drug-Eluting Stent: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Coronary Drug-Eluting Stent Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Polymer Stent
1.2.3 Polymer-Free Stent
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Coronary Drug-Eluting Stent Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Coronary Drug-Eluting Stent Revenue Estimates and Forecasts 2020-2031
2.2 Global Coronary Drug-Eluting Stent Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Coronary Drug-Eluting Stent Sales Estimates and Forecasts 2020-2031
2.4 Global Coronary Drug-Eluting Stent Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Coronary Drug-Eluting Stent Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Coronary Drug-Eluting Stent Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Polymer Stent Market Size by Manufacturers
3.5.2 Polymer-Free Stent Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Coronary Drug-Eluting Stent Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Coronary Drug-Eluting Stent Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Coronary Drug-Eluting Stent Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Coronary Drug-Eluting Stent Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Coronary Drug-Eluting Stent Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
6.4 North America Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Coronary Drug-Eluting Stent Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
7.4 Europe Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Coronary Drug-Eluting Stent Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Coronary Drug-Eluting Stent Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
9.4 Central and South America Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Coronary Drug-Eluting Stent Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Coronary Drug-Eluting Stent Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Coronary Drug-Eluting Stent Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Coronary Drug-Eluting Stent Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Medtronic
11.1.1 Medtronic Corporation Information
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.1.4 Medtronic Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Medtronic Coronary Drug-Eluting Stent Sales by Product in 2024
11.1.6 Medtronic Coronary Drug-Eluting Stent Sales by Application in 2024
11.1.7 Medtronic Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.1.8 Medtronic Coronary Drug-Eluting Stent SWOT Analysis
11.1.9 Medtronic Recent Developments
11.2 Boston Scientific
11.2.1 Boston Scientific Corporation Information
11.2.2 Boston Scientific Business Overview
11.2.3 Boston Scientific Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.2.4 Boston Scientific Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Boston Scientific Coronary Drug-Eluting Stent Sales by Product in 2024
11.2.6 Boston Scientific Coronary Drug-Eluting Stent Sales by Application in 2024
11.2.7 Boston Scientific Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.2.8 Boston Scientific Coronary Drug-Eluting Stent SWOT Analysis
11.2.9 Boston Scientific Recent Developments
11.3 Abbott
11.3.1 Abbott Corporation Information
11.3.2 Abbott Business Overview
11.3.3 Abbott Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.3.4 Abbott Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Abbott Coronary Drug-Eluting Stent Sales by Product in 2024
11.3.6 Abbott Coronary Drug-Eluting Stent Sales by Application in 2024
11.3.7 Abbott Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.3.8 Abbott Coronary Drug-Eluting Stent SWOT Analysis
11.3.9 Abbott Recent Developments
11.4 B.Braun
11.4.1 B.Braun Corporation Information
11.4.2 B.Braun Business Overview
11.4.3 B.Braun Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.4.4 B.Braun Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 B.Braun Coronary Drug-Eluting Stent Sales by Product in 2024
11.4.6 B.Braun Coronary Drug-Eluting Stent Sales by Application in 2024
11.4.7 B.Braun Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.4.8 B.Braun Coronary Drug-Eluting Stent SWOT Analysis
11.4.9 B.Braun Recent Developments
11.5 Biosensors International
11.5.1 Biosensors International Corporation Information
11.5.2 Biosensors International Business Overview
11.5.3 Biosensors International Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.5.4 Biosensors International Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Biosensors International Coronary Drug-Eluting Stent Sales by Product in 2024
11.5.6 Biosensors International Coronary Drug-Eluting Stent Sales by Application in 2024
11.5.7 Biosensors International Coronary Drug-Eluting Stent Sales by Geographic Area in 2024
11.5.8 Biosensors International Coronary Drug-Eluting Stent SWOT Analysis
11.5.9 Biosensors International Recent Developments
11.6 MicroPort
11.6.1 MicroPort Corporation Information
11.6.2 MicroPort Business Overview
11.6.3 MicroPort Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.6.4 MicroPort Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 MicroPort Recent Developments
11.7 Lepu Medical
11.7.1 Lepu Medical Corporation Information
11.7.2 Lepu Medical Business Overview
11.7.3 Lepu Medical Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.7.4 Lepu Medical Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Lepu Medical Recent Developments
11.8 Terumo
11.8.1 Terumo Corporation Information
11.8.2 Terumo Business Overview
11.8.3 Terumo Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.8.4 Terumo Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Terumo Recent Developments
11.9 Blue Sail Medical
11.9.1 Blue Sail Medical Corporation Information
11.9.2 Blue Sail Medical Business Overview
11.9.3 Blue Sail Medical Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.9.4 Blue Sail Medical Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Blue Sail Medical Recent Developments
11.10 SINOMED
11.10.1 SINOMED Corporation Information
11.10.2 SINOMED Business Overview
11.10.3 SINOMED Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.10.4 SINOMED Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 SINOMED Recent Developments
11.11 Liaoning Yinyi Biological
11.11.1 Liaoning Yinyi Biological Corporation Information
11.11.2 Liaoning Yinyi Biological Business Overview
11.11.3 Liaoning Yinyi Biological Coronary Drug-Eluting Stent Product Models, Descriptions and Specifications
11.11.4 Liaoning Yinyi Biological Coronary Drug-Eluting Stent Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Liaoning Yinyi Biological Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Coronary Drug-Eluting Stent Industry Chain
12.2 Coronary Drug-Eluting Stent Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Coronary Drug-Eluting Stent Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Coronary Drug-Eluting Stent Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Coronary Drug-Eluting Stent Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Coronary Drug-Eluting Stent Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Coronary Drug-Eluting Stent Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Coronary Drug-Eluting Stent Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Coronary Drug-Eluting Stent Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Coronary Drug-Eluting Stent Sales by Region (2020-2025) & (K Units)
Table 8. Global Coronary Drug-Eluting Stent Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Coronary Drug-Eluting Stent Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Coronary Drug-Eluting Stent Sales Share by Manufacturers (2020-2025)
Table 12. Global Coronary Drug-Eluting Stent Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Coronary Drug-Eluting Stent Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Coronary Drug-Eluting Stent by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Coronary Drug-Eluting Stent as of 2024)
Table 16. Global Coronary Drug-Eluting Stent Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Coronary Drug-Eluting Stent Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Coronary Drug-Eluting Stent Manufacturing Base and Headquarters
Table 19. Global Coronary Drug-Eluting Stent Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Coronary Drug-Eluting Stent Sales by Type (2020-2025) & (K Units)
Table 23. Global Coronary Drug-Eluting Stent Sales by Type (2026-2031) & (K Units)
Table 24. Global Coronary Drug-Eluting Stent Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Coronary Drug-Eluting Stent Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Coronary Drug-Eluting Stent ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Coronary Drug-Eluting Stent Sales by Application (2020-2025) & (K Units)
Table 29. Global Coronary Drug-Eluting Stent Sales by Application (2026-2031) & (K Units)
Table 30. Coronary Drug-Eluting Stent High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Coronary Drug-Eluting Stent Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Coronary Drug-Eluting Stent Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Coronary Drug-Eluting Stent ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 37. North America Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 40. Europe Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 45. Southeast Asia Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Coronary Drug-Eluting Stent Investment Opportunities and Key Challenges
Table 47. Central and South America Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Coronary Drug-Eluting Stent Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Medtronic Corporation Information
Table 51. Medtronic Description and Major Businesses
Table 52. Medtronic Product Models, Descriptions and Specifications
Table 53. Medtronic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Medtronic Sales Value Proportion by Product in 2024
Table 55. Medtronic Sales Value Proportion by Application in 2024
Table 56. Medtronic Sales Value Proportion by Geographic Area in 2024
Table 57. Medtronic Coronary Drug-Eluting Stent SWOT Analysis
Table 58. Medtronic Recent Developments
Table 59. Boston Scientific Corporation Information
Table 60. Boston Scientific Description and Major Businesses
Table 61. Boston Scientific Product Models, Descriptions and Specifications
Table 62. Boston Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Boston Scientific Sales Value Proportion by Product in 2024
Table 64. Boston Scientific Sales Value Proportion by Application in 2024
Table 65. Boston Scientific Sales Value Proportion by Geographic Area in 2024
Table 66. Boston Scientific Coronary Drug-Eluting Stent SWOT Analysis
Table 67. Boston Scientific Recent Developments
Table 68. Abbott Corporation Information
Table 69. Abbott Description and Major Businesses
Table 70. Abbott Product Models, Descriptions and Specifications
Table 71. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Abbott Sales Value Proportion by Product in 2024
Table 73. Abbott Sales Value Proportion by Application in 2024
Table 74. Abbott Sales Value Proportion by Geographic Area in 2024
Table 75. Abbott Coronary Drug-Eluting Stent SWOT Analysis
Table 76. Abbott Recent Developments
Table 77. B.Braun Corporation Information
Table 78. B.Braun Description and Major Businesses
Table 79. B.Braun Product Models, Descriptions and Specifications
Table 80. B.Braun Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. B.Braun Sales Value Proportion by Product in 2024
Table 82. B.Braun Sales Value Proportion by Application in 2024
Table 83. B.Braun Sales Value Proportion by Geographic Area in 2024
Table 84. B.Braun Coronary Drug-Eluting Stent SWOT Analysis
Table 85. B.Braun Recent Developments
Table 86. Biosensors International Corporation Information
Table 87. Biosensors International Description and Major Businesses
Table 88. Biosensors International Product Models, Descriptions and Specifications
Table 89. Biosensors International Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Biosensors International Sales Value Proportion by Product in 2024
Table 91. Biosensors International Sales Value Proportion by Application in 2024
Table 92. Biosensors International Sales Value Proportion by Geographic Area in 2024
Table 93. Biosensors International Coronary Drug-Eluting Stent SWOT Analysis
Table 94. Biosensors International Recent Developments
Table 95. MicroPort Corporation Information
Table 96. MicroPort Description and Major Businesses
Table 97. MicroPort Product Models, Descriptions and Specifications
Table 98. MicroPort Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. MicroPort Recent Developments
Table 100. Lepu Medical Corporation Information
Table 101. Lepu Medical Description and Major Businesses
Table 102. Lepu Medical Product Models, Descriptions and Specifications
Table 103. Lepu Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Lepu Medical Recent Developments
Table 105. Terumo Corporation Information
Table 106. Terumo Description and Major Businesses
Table 107. Terumo Product Models, Descriptions and Specifications
Table 108. Terumo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Terumo Recent Developments
Table 110. Blue Sail Medical Corporation Information
Table 111. Blue Sail Medical Description and Major Businesses
Table 112. Blue Sail Medical Product Models, Descriptions and Specifications
Table 113. Blue Sail Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Blue Sail Medical Recent Developments
Table 115. SINOMED Corporation Information
Table 116. SINOMED Description and Major Businesses
Table 117. SINOMED Product Models, Descriptions and Specifications
Table 118. SINOMED Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. SINOMED Recent Developments
Table 120. Liaoning Yinyi Biological Corporation Information
Table 121. Liaoning Yinyi Biological Description and Major Businesses
Table 122. Liaoning Yinyi Biological Product Models, Descriptions and Specifications
Table 123. Liaoning Yinyi Biological Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Liaoning Yinyi Biological Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Coronary Drug-Eluting Stent Product Picture
Figure 2. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Polymer Stent Product Picture
Figure 4. Polymer-Free Stent Product Picture
Figure 5. Others Product Picture
Figure 6. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Coronary Drug-Eluting Stent Report Years Considered
Figure 10. Global Coronary Drug-Eluting Stent Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 12. Global Coronary Drug-Eluting Stent Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Coronary Drug-Eluting Stent Revenue Market Share by Region (2020-2031)
Figure 14. Global Coronary Drug-Eluting Stent Sales (2020-2031) & (K Units)
Figure 15. Global Coronary Drug-Eluting Stent Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Coronary Drug-Eluting Stent Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Coronary Drug-Eluting Stent Sales Volume Market Share in 2024
Figure 18. Global Coronary Drug-Eluting Stent Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Polymer Stent Revenue Market Share by Manufacturer in 2024
Figure 21. Polymer-Free Stent Revenue Market Share by Manufacturer in 2024
Figure 22. Others Revenue Market Share by Manufacturer in 2024
Figure 23. Global Coronary Drug-Eluting Stent Sales Market Share by Type (2020-2031)
Figure 24. Global Coronary Drug-Eluting Stent Revenue Market Share by Type (2020-2031)
Figure 25. Global Coronary Drug-Eluting Stent Sales Market Share by Application (2020-2031)
Figure 26. Global Coronary Drug-Eluting Stent Revenue Market Share by Application (2020-2031)
Figure 27. North America Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 28. North America Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 30. North America Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 40. Europe Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 45. France Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 60. India Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 81. Coronary Drug-Eluting Stent Industry Chain Mapping
Figure 82. Regional Coronary Drug-Eluting Stent Manufacturing Base Distribution (%)
Figure 83. Global Coronary Drug-Eluting Stent Production Market Share by Region (2020-2031)
Figure 84. Coronary Drug-Eluting Stent Production Process
Figure 85. Regional Coronary Drug-Eluting Stent Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Table 1. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Coronary Drug-Eluting Stent Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Coronary Drug-Eluting Stent Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Coronary Drug-Eluting Stent Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Coronary Drug-Eluting Stent Sales by Region (2020-2025) & (K Units)
Table 8. Global Coronary Drug-Eluting Stent Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Coronary Drug-Eluting Stent Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Coronary Drug-Eluting Stent Sales Share by Manufacturers (2020-2025)
Table 12. Global Coronary Drug-Eluting Stent Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Coronary Drug-Eluting Stent Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Coronary Drug-Eluting Stent by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Coronary Drug-Eluting Stent as of 2024)
Table 16. Global Coronary Drug-Eluting Stent Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Coronary Drug-Eluting Stent Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Coronary Drug-Eluting Stent Manufacturing Base and Headquarters
Table 19. Global Coronary Drug-Eluting Stent Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Coronary Drug-Eluting Stent Sales by Type (2020-2025) & (K Units)
Table 23. Global Coronary Drug-Eluting Stent Sales by Type (2026-2031) & (K Units)
Table 24. Global Coronary Drug-Eluting Stent Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Coronary Drug-Eluting Stent Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Coronary Drug-Eluting Stent ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Coronary Drug-Eluting Stent Sales by Application (2020-2025) & (K Units)
Table 29. Global Coronary Drug-Eluting Stent Sales by Application (2026-2031) & (K Units)
Table 30. Coronary Drug-Eluting Stent High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Coronary Drug-Eluting Stent Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Coronary Drug-Eluting Stent Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Coronary Drug-Eluting Stent ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 37. North America Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 40. Europe Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Coronary Drug-Eluting Stent Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Coronary Drug-Eluting Stent Growth Accelerators and Market Barriers
Table 45. Southeast Asia Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Coronary Drug-Eluting Stent Investment Opportunities and Key Challenges
Table 47. Central and South America Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Coronary Drug-Eluting Stent Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Coronary Drug-Eluting Stent Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Medtronic Corporation Information
Table 51. Medtronic Description and Major Businesses
Table 52. Medtronic Product Models, Descriptions and Specifications
Table 53. Medtronic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Medtronic Sales Value Proportion by Product in 2024
Table 55. Medtronic Sales Value Proportion by Application in 2024
Table 56. Medtronic Sales Value Proportion by Geographic Area in 2024
Table 57. Medtronic Coronary Drug-Eluting Stent SWOT Analysis
Table 58. Medtronic Recent Developments
Table 59. Boston Scientific Corporation Information
Table 60. Boston Scientific Description and Major Businesses
Table 61. Boston Scientific Product Models, Descriptions and Specifications
Table 62. Boston Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Boston Scientific Sales Value Proportion by Product in 2024
Table 64. Boston Scientific Sales Value Proportion by Application in 2024
Table 65. Boston Scientific Sales Value Proportion by Geographic Area in 2024
Table 66. Boston Scientific Coronary Drug-Eluting Stent SWOT Analysis
Table 67. Boston Scientific Recent Developments
Table 68. Abbott Corporation Information
Table 69. Abbott Description and Major Businesses
Table 70. Abbott Product Models, Descriptions and Specifications
Table 71. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Abbott Sales Value Proportion by Product in 2024
Table 73. Abbott Sales Value Proportion by Application in 2024
Table 74. Abbott Sales Value Proportion by Geographic Area in 2024
Table 75. Abbott Coronary Drug-Eluting Stent SWOT Analysis
Table 76. Abbott Recent Developments
Table 77. B.Braun Corporation Information
Table 78. B.Braun Description and Major Businesses
Table 79. B.Braun Product Models, Descriptions and Specifications
Table 80. B.Braun Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. B.Braun Sales Value Proportion by Product in 2024
Table 82. B.Braun Sales Value Proportion by Application in 2024
Table 83. B.Braun Sales Value Proportion by Geographic Area in 2024
Table 84. B.Braun Coronary Drug-Eluting Stent SWOT Analysis
Table 85. B.Braun Recent Developments
Table 86. Biosensors International Corporation Information
Table 87. Biosensors International Description and Major Businesses
Table 88. Biosensors International Product Models, Descriptions and Specifications
Table 89. Biosensors International Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Biosensors International Sales Value Proportion by Product in 2024
Table 91. Biosensors International Sales Value Proportion by Application in 2024
Table 92. Biosensors International Sales Value Proportion by Geographic Area in 2024
Table 93. Biosensors International Coronary Drug-Eluting Stent SWOT Analysis
Table 94. Biosensors International Recent Developments
Table 95. MicroPort Corporation Information
Table 96. MicroPort Description and Major Businesses
Table 97. MicroPort Product Models, Descriptions and Specifications
Table 98. MicroPort Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. MicroPort Recent Developments
Table 100. Lepu Medical Corporation Information
Table 101. Lepu Medical Description and Major Businesses
Table 102. Lepu Medical Product Models, Descriptions and Specifications
Table 103. Lepu Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Lepu Medical Recent Developments
Table 105. Terumo Corporation Information
Table 106. Terumo Description and Major Businesses
Table 107. Terumo Product Models, Descriptions and Specifications
Table 108. Terumo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Terumo Recent Developments
Table 110. Blue Sail Medical Corporation Information
Table 111. Blue Sail Medical Description and Major Businesses
Table 112. Blue Sail Medical Product Models, Descriptions and Specifications
Table 113. Blue Sail Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Blue Sail Medical Recent Developments
Table 115. SINOMED Corporation Information
Table 116. SINOMED Description and Major Businesses
Table 117. SINOMED Product Models, Descriptions and Specifications
Table 118. SINOMED Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. SINOMED Recent Developments
Table 120. Liaoning Yinyi Biological Corporation Information
Table 121. Liaoning Yinyi Biological Description and Major Businesses
Table 122. Liaoning Yinyi Biological Product Models, Descriptions and Specifications
Table 123. Liaoning Yinyi Biological Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Liaoning Yinyi Biological Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Coronary Drug-Eluting Stent Product Picture
Figure 2. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Polymer Stent Product Picture
Figure 4. Polymer-Free Stent Product Picture
Figure 5. Others Product Picture
Figure 6. Global Coronary Drug-Eluting Stent Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Coronary Drug-Eluting Stent Report Years Considered
Figure 10. Global Coronary Drug-Eluting Stent Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 12. Global Coronary Drug-Eluting Stent Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Coronary Drug-Eluting Stent Revenue Market Share by Region (2020-2031)
Figure 14. Global Coronary Drug-Eluting Stent Sales (2020-2031) & (K Units)
Figure 15. Global Coronary Drug-Eluting Stent Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Coronary Drug-Eluting Stent Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Coronary Drug-Eluting Stent Sales Volume Market Share in 2024
Figure 18. Global Coronary Drug-Eluting Stent Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Polymer Stent Revenue Market Share by Manufacturer in 2024
Figure 21. Polymer-Free Stent Revenue Market Share by Manufacturer in 2024
Figure 22. Others Revenue Market Share by Manufacturer in 2024
Figure 23. Global Coronary Drug-Eluting Stent Sales Market Share by Type (2020-2031)
Figure 24. Global Coronary Drug-Eluting Stent Revenue Market Share by Type (2020-2031)
Figure 25. Global Coronary Drug-Eluting Stent Sales Market Share by Application (2020-2031)
Figure 26. Global Coronary Drug-Eluting Stent Revenue Market Share by Application (2020-2031)
Figure 27. North America Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 28. North America Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 30. North America Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 38. Europe Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 40. Europe Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 45. France Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 60. India Coronary Drug-Eluting Stent Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Coronary Drug-Eluting Stent Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa Coronary Drug-Eluting Stent Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Coronary Drug-Eluting Stent Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Coronary Drug-Eluting Stent Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Coronary Drug-Eluting Stent Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa Coronary Drug-Eluting Stent Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Coronary Drug-Eluting Stent Revenue (2020-2025) & (US$ Million)
Figure 81. Coronary Drug-Eluting Stent Industry Chain Mapping
Figure 82. Regional Coronary Drug-Eluting Stent Manufacturing Base Distribution (%)
Figure 83. Global Coronary Drug-Eluting Stent Production Market Share by Region (2020-2031)
Figure 84. Coronary Drug-Eluting Stent Production Process
Figure 85. Regional Coronary Drug-Eluting Stent Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232